Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (12,065,538)	$ (1,696,890)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued for services rendered by consultants		$ 3,570
Stock issued for interest
Stock issued for expenses		$ (48,000)
Interest Expense attributable to amortization of discount	$ 77,419
Changes in operating assets and liabilities:
(Increase) Decrease in Prepaid Expenses	(6,289)
Increase (Decrease) in Accounts Payable	(14,830)	$ 5,902
Increase (Decrease) in Accrued Expenses	140,804	$ (37,581)
Increase (Decrease) in bank Overdraft	(6,137)
(Increase) Decrease in Interest Receivable	$ (848)	$ (14)
Increase (Decrease) in Due to Affiliate		(34,895)
(Increase) Decrease in Note Receivable	$ (1,629)	(2,222)
Net Cash Provided by (Used in) Operating Activities	(11,877,048)	(1,713,750)
CASH FLOWS FROM FINANCING ACTIVITIES
Additional paid in Capital	681,274	300,000
Increase (Decrease) in due to subsidiary shareholder	0	100,000
Principal borrowings (repayments) on notes and Convertible Debentures	60,103	$ 246,360
Principal borrowings (repayments) on Convertible Debentures	$ 1,272,686
(Increase) Decrease in Deferred Financing Costs		$ 65,000
Loss on Settlement of Debt through Equity Issuance	$ 10,093,387	984,730
Net Cash Provided by (Used in) Financing Activities	12,107,450	1,696,090
Net Increase (Decrease) in Cash	230,402	(17,660)
Cash at Beginning of Period	502	116,714
Cash at End of Period	230,904	99,054
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	157,500	$ 83,000
Common Shares of Regen Biopharma, Inc. Issued for Debt	$ 972,686